TP53 and esophageal squamous cell carcinoma: Furthermore, in the same study, it was observed that cisplatin, the main chemotherapeutic agent used in EC management, was able to revert the invasive phenotype of ESCC cells, due to the induction of ATF3 expression occurring through p53 intermediation.